An Isoniazid Analogue Promotes Mycobacterium tuberculosis-Nanoparticle Interactions and Enhances Bacterial Killing by Macrophages

Tatiany J. de Faria, Mariane Roman, Nicole M. de Souza, Rodrigo De Vecchi, João Vitor de Assis, Ana Lúcia Gomes dos Santos, Ivan H. Bechtold, Nathalie Winter, Maurilio José Soares, Luciano Paulino Silva, Mauro V. De Almeida, and André Báfica

Laboratory of Immunobiology, Department of Microbiology, Immunology and Parasitology, Universidade Federal de Santa Catarina (UFSC), Florianópolis, Brazil; Laboratory of Cell Biology, Carlos Chagas Institute/FIOCRUZ, Paraná, Brazil; and Laboratory of Mass Spectrometry, EMBRAPA, Genetic Resources and Biotechnology, Brasília, Brazil

Nanoeponed drug delivery systems against tuberculosis (TB) are thought to control pathogen replication by targeting antibiotics to infected tissues and phagocytes. However, whether nanoparticle (NP)-based carriers directly interact with Mycobacterium tuberculosis and how such drug delivery systems induce intracellular bacterial killing by macrophages is not defined. In the present study, we demonstrated that a highly hydrophobic citral-derived isoniazid analogue, termed JVA, significantly increases therapy during active TB.

Mycobacterium tuberculosis is a major human pathogen which infects one-third of the world’s population and causes tuberculosis (TB) in 9.4 million people each year (13, 49). Multidrug chemotherapy has been used for more than 50 years, and isoniazid (INH) has been shown to be one of the most effective antimycobacterial compounds (31, 39). Although such effective drugs are available throughout the world, several factors, including drug toxicity and poor patient compliance, may contribute to the emergence of multidrug-resistant (MDR) strains (18, 24). In 2008, MDR-TB caused an estimated 150,000 deaths (16, 50), which seriously affects public health worldwide, indicating that while an effective TB vaccine has not been discovered, strategies such as the development of novel drugs (5, 40), the modification of old drugs (24), and the generation of new delivery systems (37, 45) are needed.

More recently, nanotechnology-based strategies have been employed in an attempt to increase drug cell targeting, thus reducing chemotherapy-associated side effects and enhancing the containment of infection (28, 29). In the case of TB, nanoeponed drug delivery systems are thought to reach mycobacteria within granulomas during active disease and decrease time as well as dose compared to the currently used multidrug toxic combination (18, 37). Different nanocarriers have been developed for the delivery of several antimycobacterial antibiotics (7, 45), and poly-lactide-coglycolic acid (PLGA)-based particles encapsulated with INH are among the most studied (37). For example, compared to soluble INH exposure, it has been demonstrated that M. tuberculosis-infected animals treated with biodegradable polymeric drug carriers display decreased bacterial growth in tissues (12, 36). In addition, when INH was associated with nanoparticles (NPs), a lower dose of INH appeared to be sufficient to enhance M. tuberculosis killing (43). These pieces of evidence suggest that drug NPs promote enhanced mycobacterial killing in a lower-dose system, which would decrease side effects, improve patient compliance, and thus affect the development of drug resistance (7, 18, 37, 45). Although it has been thought that nanoeponed systems should be tested against active TB, there remains a paucity of information on how antibiotic NPs interact with M. tuberculosis at the cellular level.

M. tuberculosis infection begins with bacterial uptake by phagocytes, such as macrophages at the primary site of exposure (9, 46). Following infection, a complex myriad of cellular interactions leads to granuloma formation, which is critical to contain mycobacterial proliferation (11, 14). However, factors such as HIV coinfected, undernourishment, and primary immune deficiencies establish an environment that may enhance bacterial growth, leading to active disease and bacterial dissemination (10, 41, 42). During active TB, for example, high numbers of M. tuberculosis are found in necrotic granulomas (19, 21, 34), which may be difficult areas to be appropriately reached by drugs during chemotherapy (34, 46). Taken together, these observations point out that anti-TB nanoeponed systems should be designed to target antibiotics into mycobacteria, which may be found in the extracellular milieu and/or in intracellular compartments (19, 46). In addition, chemical modifications of currently used drugs can be
performed to enhance drug-NP interactions with *M. tuberculosis* and macrophages harboring bacteria. However, whether antibiotic NP directly interacts with *M. tuberculosis* outside and inside macrophages has not been formally demonstrated.

In the present study, we have developed a novel antimycobacterial drug-NP carrier which displays high activity against extra- and intracellular mycobacteria. In addition, the observed anti-TB effects were associated with increased cellular interactions of NPs and bacteria, probably by enhancing intracellular bioavailability of a citral-derived INH analogue. These findings provide evidence that nanoenabled carriers are generated to target both extra- and intracellular mycobacteria.

**MATERIALS AND METHODS**

**JVA, synthesis, and log *P* measurements.** Isoniazid (Sigma-Aldrich) (3.5 g; 25.6 mmol) was added to a solution of citral (a commercial mixture of geraniol and neral; 3.0 g; 19.7 mmol) diluted in 50 ml of anhydrous methanol (MeOH). The reaction mixture was stirred at 60°C for 24 h, followed by concentration under reduced pressure and the addition of ethyl ether (25 ml). After 48 h at room temperature, the solid formed was isolated by filtration and dried to yield the compound *E*-2,3,7,3′,5′,6-octadecylideneisonicotinic acid hydrazide (JVA) (3.2 g; 6.0% yield). Melt point, 126 to 128°C. IR (KBr): 3,044 (C-Harom.), 2,982 (C-Haliphatic), 1,700 (C=O). 1H nuclear magnetic resonance (NMR) (300 MHz, CDCl3): δ 1.5 to 1.7 (3H, CH3), 2.1 (s, 4H, H5), 5.0 (s, 1H, H6), 5.9 (d, 1H, H2, J=9.6 Hz), 7.7 (d, 2H, H5′, H9′), 8.5 (d, 1H, H1), 8.6 (d, 2H, H6′, H8′) 11.6 (s, 1H, NH). 13C NMR (75 MHz, CDCl3): δ 14.7, 17.8, (C10, C8), 25.7, 26.2 (C5, C9), 40.3 (C4), 121.4 to 123.1 (C2, C5′, C9′, C6), 132.5 (C7), 140.4 (C1), 150.1 to 151.6 (C4′, C6′, C8′, C3), 162.9 (C3′).

Partition coefficient oil/water experiments of INH and JVA were determined using dichloromethane (J.T. Baker) as the organic phase (oil) (30). Two milligrams of INH or JVA was transferred to microtubes and sonicated (50 W) for 3 min at 50°C. Drug content (mg/mL) was added into a 10-ml 1% (wt/vol) polyvinyl alcohol (PVA, Sigma) solution. This mixture was employed using acetonitrile buffer (J.T. Baker) with 50 mM KH2PO4, pH 3.5 (65:35 vol/vol), or acetonitrile buffer with 50 mM KH2PO4, pH 3.5 (03:97 vol/vol), respectively, with an isocratic elution mode at a flow rate of 1 ml -min⁻¹. To measure drug contents in nanoparticles, JVA-NP or INH-NP pellets were dissolved in dimethyl sulfoxide (DMSO) (1 ml) and sonicated for 1 min at 50 W. Drug content (µg -ml⁻¹) measurements from total NP suspensions, NP pellets, or supernatants were obtained in 100-µl aliquots diluted in defined mobile phase following filtration in 0.45-µm membranes. Samples were analyzed in triplicate by HPLC, and drug concentrations were calculated using a standard curve. Entrainment efficiency (EE) was calculated as the difference between the total drug amount (mg) from total NP suspension versus that of supernatants ([total drug amount (mg)]-[supernatant (mg)]/[total drug amount (mg)]) × 100. Drug content was calculated by means of the amount of compound measured in the pellet. The HPLC method was previously validated, and linear calibration curves for JVA and INH were obtained in the range of 1.56 to 100 µg·ml⁻¹, presenting correlation coefficients greater than 0.998 (data not shown).

**JVA-NP-macrophage association studies. (i) Flow cytometry.** Murine bone marrow-derived macrophages (BMMs; 5 × 10⁵ cells/ml) generated previously described (4) were infected with *M. tuberculosis* variant *bovis* BCG strain Pasteur expressing the red fluorescent protein dsRed1 (BCG-RFP) (1, 14) (multiplicity of infection [MOI], 10) for 3 h in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) containing 10% fetal bovine serum (FBS; HyClone), 2 mM L-glutamine, 10 mM HEPES (all from Gibco). Cells were washed with phosphate-buffered saline (PBS) (Gibco) and exposed to FITC-NP for 2 h. After that, macrophages were washed with PBS and suspended in PBS–1% fetal bovine serum (FBS) (fluorescence-activated cell sorter [FACS] buffer). Cells were acquired on a FACSCalibur or FACSCanuto II (Becton Dickinson) flow cytometer and analyzed with FlowJo 8.6.3 software (Tree Star, Inc., Ashland, OR). To analyze NPs associated with mycobacterium-infected cells, events were first gated on cell populations based on forward scatter (FSC) and side scatter (SSC) parameters and then on FL-2 (RFP-BCG)-positive events versus SSC. FL2⁺ cells were then gated, and FL-1 (FITC-NP) was employed in histograms. In all experiments performed, infected cells untreated or exposed to unlabeled NPs (empty control) were utilized as negative controls and to guide the gating strategy.

**JVA-NP-macrophage association studies. (ii) Confocal laser-scanning microscopy.** DMEM–cultured BMMs (5 × 10⁵ cells/ml) adhered onto coverslips were infected with BCG-RFP (MOI, 1) and incubated for 3 h. Macrophages then were washed 3 times with DMEM and exposed to FITC-NPs for 1 h at 37°C. Cells were washed, labeled with 4′-6-diamidino-2-phenyindole (DAPI) (Molecular Probes), and recovered with antifading reagent (Molecular Probes). Images were
acquired on a Leica TCS SPS, which is a confocal microscope (Leica Microsystems, IL). Representative cells were selected and a series of optical sections (2 sections) were taken. Images captured in DAPI, rTRF, and FITC channels were overlaid to determine the colocalization of FITC-NP as well as BCG-RFP.

(iii) Intracellular bioavailability studies. Murine BMMs (5 × 10^5 cells/ml) were exposed to JVA or JVA-NPs (diluted in DMEM) at a final concentration of 200 μg · ml⁻¹ of IVA. Following 3 h of incubation, cells were washed five times with PBS and lysed by six cycles of freeze-thawing. JVA extraction from cell lysates was performed as previously described (48), with minor modifications. Briefly, 50 μl of 20% (wt/vol) NaCl solution was added to 200 μl of cell lysate. After the addition of chloroform-butanol (70:30, vol/vol) (1 ml), cell lysates were vortexed for 1 min followed by centrifugation (4,000 × g for 10 min at room temperature). Two hundred μl of aqueous phase was discarded, and the remaining organic phase was analyzed by HPLC as described above.

(iv) Antimycobacterial activity by infected macrophages. BMMs (5 × 10^5 cells/ml) were infected with the virulent strain M. tuberculosis H37Rv (MOI, 1) at 37°C containing 5% CO₂ for 4 h in complete DMEM. Cells then were washed with PBS, and new media without antibiotics were added to cultures, which were exposed to JVA or JVA-NPs (diluted in DMEM). After 7 days of incubation, the medium was removed and cells were washed and lysed using 200 μl of 1% saponin in sterile water. Cell lysates were plated on solid medium 7H10 and incubated at 37°C. After 28 days of incubation CFU were counted, and the results were expressed graphically.

JVA-NP-mycobacterium association studies. (i) Flow cytometry. One hundred μl of M. tuberculosis H37Rv suspension (10^6 bacteria/well) cultured in Löwenstein-Jensen (LI) medium, 10% oleic acid-albumin-dextrose-catalase (OADC) was added to 15-ml tubes (Falcon; BD) and exposed to NPs (nanoparticles without drug) or FITC-NPs (20 μl) for 4 h.

Bacterial suspensions were washed 3 times with PBS to remove nonassociating NPs or free JVA. Membranes containing the retentate then were placed onto plastic tubes and mixed with a saturated matrix solution of alpha-cyano-4-hydroxycinnamic acid (1:3) and spotted (0.5 μl) onto an MTP AnchorChip var/384 matrix-assisted laser desorption/ionization (MALDI) sample plate. The monoisotopic molecular mass of the IVA was determined by MALDI–time of flight tandem mass spectrometry (MALDI-TOF/MS) using an UltraFlex III (Bruker Daltonics, Germany) controlled by FlexControl 3.0 software. The MS spectra were carried out in the positive ion reflector mode at a laser frequency of 100 Hz with external calibration using the matrix ions. Data were analyzed using FlexAnalysis 3.0 software.

Statistical analysis. Nonparametric Student’s t test or one-way analysis of variance (ANOVA) test (Graphpad Software, Prism) was used to calculate the significance of differences between groups. P < 0.05 was considered statistically significant.

RESULTS JVA, a hydrophobic citral-derived INH analogue, displays antimycobacterial activity and high entrapment efficiency in PLGA nanoparticles. To study NP-antibiotic-mycobacterium-phagocyte interactions, we first employed known techniques to nanocapsulate INH using the approved PLGA polymer (Fig. 1). However, we consistently observed that this antimycobacterial drug presented a low entrapment efficiency (~20%) within the PLGA-NPs (Fig. 1). INH is a known hydrophobic molecule, and although it has long been used as an effective anti-TB drug, its low cellular penetration could contribute to the development of M. tuberculosis resistance (8, 26, 35). Therefore, the development of hydrophobic INH analogues could both enhance nanocapsulation in PLGA-based particles (32) and increase the cellular penetration of target tissues (8, 23, 25). We next aimed to increase drug hydrophobicity, and to do so we treated INH with citral in methanol to generate the corresponding hydrazine, E-N^β-3,7-dimethyl-2,6-octadienylidene isonicotinic acid hydrazide, named JVA (Fig. 2A) (20), which presents a high partition coefficient (log P) (Fig. 2B). JVA displays mycobacterial killing activity similar to that of INH as analyzed by means of CFU counts on agar plates or MTT-based assay in broth media (Fig. 2C), indicating that this compound is a candidate to generate novel nanodelivery systems against TB. PLGA-based nanoparticles displayed large amounts of JVA (4-fold increase above that of INH) as well as the enhanced entrapment efficiency of this compound (3-fold increase above that of INH) (Fig. 3A and B). Drug recovery for JVA-NPs and INH-NPs was found to present similar results (80% and ~65%, respectively) (Fig. 3C). The average diameter of JVA-NPs was approximately 180 nm with monomodal distribution (polydispersity index, <0.2; data not shown) as well as negative surface charge (~23 ±
0.9mV) (Fig. 3D and E). Evaluations employing field emission scanning electron microscopy (FESEM) and atomic force microscopy (AFM) analyses have revealed the spherical shape and smooth surface of JVA-NP formulations (Fig. 3F to I). Moreover, detailed FESEM measurements showed that JVA-NPs presented a characteristic core shell particle, suggesting that this drug is entrapped within the nanoparticle (Fig. 3G) and that this nanosystem could enhance bacterial killing inside or outside phagocytes.

**JVA-NPs enhance mycobacterial killing by macrophages and promote drug intracellular bioavailability.** During active infection, proliferating *M. tuberculosis* bacilli are found in intracellular compartments of macrophages as well as in the extracellular milieu (19, 35). To examine whether JVA-NPs are functional nanocarriers, we first studied NP-macrophage interactions. Flow cytometry and confocal microscopy analyses demonstrate that BCG-RFP-infected macrophages uptake FITC-stained NPs (Fig. 4A and B). Moreover, FITC-NPs were found to colocalize with BCG-RFP inside macrophages (Fig. 4B), suggesting that such nanocarriers directly interact with intracellular bacteria, promoting increased drug bioavailability in infected tissues. Consistently with this, increased amounts of JVA inside macrophages were found when cells were treated with JVA-NPs in vitro (Fig. 4C). Strikingly, compared to soluble JVA, JVA-NP treatment enhanced *M. tuberculosis* killing by macrophages in a dose-response manner (Fig. 4D and E). In addition, *M. tuberculosis*-infected macrophages exposed to a mixture of soluble JVA and NPs (JVA + NP),
as opposed to nanoencapsulated JVA (JVA-NP), display levels of mycobacterial killing comparable to those found in cells treated with soluble JVA (Fig. 4D, right). Taken together, these results indicate that JVA-NPs target intracellular *M. tuberculosis* and promote antibiotic delivery into macrophages.

**JVA-NPs directly enhance drug delivery in mycobacteria.** Because proliferating mycobacteria are also observed outside cells (19, 35), an efficient nanoenabled system should be able to both interact and deliver anti-TB drugs in such an environment. Figure 5A shows that FITC-stained NPs directly associate with *M. tuberculosis*. This was further demonstrated by AFM analysis of JVA-NPs and mycobacterial interaction experiments (Fig. 5B, right top). Moreover, by employing phase images (viscoelasticity) in JVA-NP-treated mycobacteria, we have observed that such carriers directly interact with the bacilli (Fig. 5B, right bottom). Detailed measurements of height profiles as well as relative viscosity performed in mycobacterial cell wall surfaces confirm the presence of nanoparticles (Fig. 5C and D). Similarly to what was observed in *M. tuberculosis*-infected macrophages (Fig. 4D and E), JVA-NPs inhibited *M. tuberculosis* growth in both time- and dose-dependent manners (Fig. 5E). These results suggest that the nanoenabled system JVA-NPs diminish pathogen proliferation by enhancing drug bioavailability in the bacterium. To test such a hypothesis, mycobacteria were left untreated or were exposed to soluble JVA or JVA-NPs. Following 1 h of incubation, samples were applied onto a 0.45-μm membrane filter system in which a set of extensive washes (30 times) have been employed to discard possible nonassociated NPs and drug (flowthrough). MALDI-TOF was employed in the membrane/retentate system (i.e., mycobacterium-associated NPs) to detect bacterially bound JVA ions. Importantly, high contents of ion JVA (*m/z* 272) remained detectable in the membrane from JVA-NP-mycobacterium samples compared to those exposed to soluble JVA (Fig. 5F) or a control in which only JVA-NPs were directly applied to the membrane filter system. Taken together, these results suggest that nanoparticles directly interact with mycobacteria and could enhance drug delivery within the pathogen.

**DISCUSSION**

The use of nanotechnology has been proposed to generate novel biodegradable nanoparticle-based anti-TB drug delivery systems (7, 18, 45). Such nanosystems are thought to target drug into *M. tuberculosis*-infected phagocytes and improve drug control release into infected tissues (27, 37). However, to develop ideal nanocarriers against TB, detailed analysis of the molecular pathways associated with nanoparticle drug-*M. tuberculosis* cell interactions may be helpful to rationally design effective nanoenabled systems. In the present study, we have developed a PLGA nanoenabled delivery system containing an INH analogue which enhances *M. tuberculosis* killing whether bacteria are located inside macrophages or outside these cells. Although INH has been utilized since 1952, this molecule is highly hydrophilic, and it is thought that it should not be used alone for TB treatment given its low cellular penetration, which is associated with the induction of bacterial resistance (26, 35). Nevertheless, INH displays a low MIC (0.05 μg · ml⁻¹), and it has been speculated that INH analogues can be further utilized to increase activity and cellular penetration (8, 25). Additionally, the use of novel analogues based on old molecules is a general idea to reduce time to generate novel TB chemotherapy. We have developed a highly hydrophobic compound,
E-N^2-3,7-dimethyl-2-E,6-octadienylidenyl isonicotinic acid hydrazide, named JVA, which was found to be significantly encapsulated in PLGA nanoparticles. Using a similar method to generate Schiff bases of INH, Hearn et al. have independently found an identical molecule with in vitro antimycobacterial activity (20).

Consistently with this, we have observed that JVA inhibits the growth of the virulent H37Rv strain in vitro at levels comparable to those of INH (Fig. 2C). Although we have not directly addressed the mechanism by which JVA decreases mycobacterial proliferation in vitro, it appears that this compound displays an effect similar to that of INH, since a clinical INH-resistant M. tuberculosis isolate (KatG S315T) was also resistant to JVA (data not shown). However, it is still possible that different mechanisms are involved in the observed mycobacterial killing by JVA, and therefore its mechanism of action remains to be fully elucidated. Theoretical and experimental analysis of JVA demonstrated partition coefficients (log P) of 3.174 and 3.203, respectively (Fig. 2B), values known to be associated with high levels of drug encapsulation in hydrophobic polymers such as PLGA (37). Taken together, these results suggest that this molecule could be further evaluated in preclinical studies. Moreover, pharmacokinetic and pharmacodynamic studies of JVA as a potential therapeutic target in TB merit further investigation.

As expected, employing nanoprecipitation-based techniques to develop PLGA nanoparticles containing JVA has shown enhanced contents of JVA encapsulation compared to that of INH. Several drug nanoencapsulation-based techniques, such as double emulsion, nanoprecipitation, and nanoprecipitation-salting out, have demonstrated various levels of INH encapsulation due to its high hydrophilicity (2, 37). In contrast, we have found that JVA presents 70 to 80% entrapment efficiency (Fig. 3B) and 4 times the drug content of INH, which shows only 20% efficiency in the same conditions. Interestingly, INH has been shown to present high entrapment efficiency in some but not all cases (2, 7), which could be explained by the use of diverse polymer and nanotechnology-based techniques (32, 37). In the present study, although we have performed different techniques and changed a number of conditions, such as pH, temperature, external phase, and polymer (Fig. 1 and data not shown), we have failed to enhance INH entrapment efficiency above 20% in PLGA particles. Nevertheless, lower levels of INH entrapment efficiency have been observed by others (2, 12), and it is well accepted in the literature that hydrophilic molecules display low entrapment efficiency in polymeric PLGA system-derived nanoparticles (17, 32). Although both soluble JVA and INH display similar MICs (1 μM), the JVA-NP MIC was found to be 3 times lower than that of INH-NPs (1.0 and 3.0 μM, respectively) (data not shown), suggesting that our novel nanoenabled system increases delivery to the pathogen compared to that of nanoencapsulated INH. Therefore, aiming for more consistent results, we have further analyzed NP-M. tuberculosis interactions using the JVA molecule as an anti-TB candidate model.

We observed that the nanoenabled system using JVA within PLGA nanoparticles enhanced M. tuberculosis killing inside macrophages. This effect was associated with increased interactions of JVA-NPs and bacteria as well as enhanced intracellular drug bioavailability. Intracellular analysis using confocal microscopy demonstrated that FITC-stained nanoparticles colocalize with mycobacteria, suggesting that such a nanocarrier traffics to bacterially associated phagosomes. Although we have not directly investigated whether nanocarriers of PLGA-JVA present enhanced intracellular interactions by macrophages, our data suggest that nanoparticles gain access to compartments containing mycobacteria.
This hypothesis is supported by observations showing nanoparticles located in nearby points where bacteria are present but not in uninfected cells, which demonstrates the intracellular spreading of nanoparticles (Fig. 4B). These experiments suggest that infected macrophages are targeted with nanoparticle-containing antibiotics, as recently suggested by Lawlor et al. (27). Consistently with this, flow cytometry data demonstrated that NP-FITC is exposed to FITC-NPs for 1 h. Following washes, cells were acquired in a flow cytometer and dot plots generated in FlowJo as described in Materials and Methods. Results represent means ± SEM of measurements from two experiments. An asterisk indicates a statistically significant difference (P < 0.05, Student’s t test) in measurements between JVA and JVA-NP. (D) M. tuberculosis H37Rv-infected macrophages were left untreated or were exposed to increased concentrations (0, 3, 30, or 300 μM) of JVA or JVA-NP for 7 days, and CFU counts were performed as described in Materials and Methods. Results represent pooled data from three independent experiments. An asterisk indicates a statistically significant difference (P < 0.05 by one-way ANOVA) in measurements between the different concentrations of JVA-NP (dose-response curve). The image on the right demonstrates the experiment described, in which cells were treated with JVA, JVA-NP, or a mixture of JVA with NPs (300 μM drug). (E) Representative CFU plates from experiment described for panel D. DIC, differential interference contrast.

JVA-NPs directly interact with M. tuberculosis. Moreover, JVA was found to be associated with mycobacterial cell walls following exposure to JVA-NPs, suggesting that drug delivery is enhanced in bacterial cultures exposed to nanocarriers. Taken together, these data demonstrate that it is possible to generate nanosystems to target intra- and extracellular mycobacteria, which could contribute to increase bacterial killing within granulomas at lower drug doses. Although we have not investigated the ultrastructure of mycobacteria treated with JVA-NP, it has been previously demonstrated that antibiotic treatment promotes changes in the bacterium (3, 47). Moreover, physical and biochemical mechanisms by which JVA-NP interacts with M. tuberculosis merits further investigation. Based on our evidence, we speculate that it is possible that PLGA nanoparticles directly access the mycobacterial membrane, enhancing intracellular drug bioavailability.

Our findings demonstrate the development of nanoenabled anti-TB systems that enhance drug targeting in extra- or intracellular mycobacteria, probably due to direct interactions between nanoparticles and the bacilli. These observations suggest that it is critical that we understand M. tuberculosis-nanoparticle interactions as a potential pharmacologic intervention for enhancing the control of pathogen replication during active TB. In this regard, it should be noted that nanocarrier systems are already in clinical
trials for cancer and some infectious diseases (29, 38), therefore it may be possible to generate nanoenabled anti-TB systems to test the efficacy of this strategy for intervention in TB.

ACKNOWLEDGMENTS

This work was supported by CAPES/NANOBIOTEC (NANOTB 23038.021356 and 23038.019088 and NANOBIOMED 705/2009), CNPq (Universal 477857, 507205, and 576948), and FIOCRUZ. M.J.S., L.P.S., M.V.A., and A.B. are investigators of CNPq (PQ-CNPq).

We thank Anicleto Poli, Marta E. R. Dosso, and Jonatan Ersching for helpful advice and technical support during the development of this work. We thank the UFSC Microscopy Center and LAMEB-CCB personnel for technical assistance.

We have no conflicts of interest.

REFERENCES


